Ritlecitinib　has　been　approved　by　the　U.S.　Food　and　Drug　Administration　(FDA)　for　the　treatment　of　severe　alopecia　areata　in　adults　and　adolescents　12　years　and　older,　which　has　become　a　promising　treatment.　Given　their　widespread　clinical　use,　a　comprehensive　real-world　study　of　their　adverse　events　(AEs)　is　warranted.　This　study　aims　to　offer　insights　into　the　characteristics　of　ritlecitinib＇s　association　with　AEs.　Disproportionality　metrics,　including　the　reporting　odds　ratio,　proportional　reporting　ratio,　information　component,　and　empirical　Bayesian　geometric　mean,　were　employed　in　our　study.　AE　signals　are　determined　by　using　these　algorithms.　The　database　for　analysis,　sourced　from　the　FDA　Adverse　Event　Reporting　System　(FAERS),　covers　the　period　from　the　first　quarter　of　2023　to　the　fourth　quarter　of　2024.　A　total　of　12　390　AEs　were　identified,　with　18　positive　signal　PTs　in　our　study.　The　common　AEs　comprised　headache　(n　=　39,　ROR　3.22),　blood　creatine　phosphokinase　increased　(n　=　24,　ROR　57.42),　urticaria　(n　=　21,　ROR　6.02),　acne　(n　=　15,　ROR　13.13),　infection　(n　=　13,　ROR　3.51),　drug　hypersensitivity　(n　=　13,　ROR　3.49),　among　other　AEs.　Notably,　five　new　and　unexpected　significant　AEs　that　were　off-label　were　also　found,　including　diabetes　mellitus,　hair　color　changes,　thyroid　disorder,　blood　cholesterol　abnormality,　and　increased　lipids.　Our　study　could　provide　a　comprehensive　safety　overview　of　ritlecitinib　during　patient　treatment　and　guide　its　clinical　practice.